MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2022.11.009

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2022

Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.

Subramanian Janakiraman, Leighl Natasha B, Choi Yoon-La, Chou Teh-Ying, Gregg Jeffrey, Hui Rina, Marchetti Antonio, Silvey Mark, Makin Rebecca, Gillespie-Akar Liane, Taylor Aliki, Kahangire Doreen A, Bailey Tom, Chau Maiyan, Navani Neal

Наблюдательное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Epidermal growth factor receptor (EGFR) mutations (EGFRm) are common oncogene drivers in non-small cell lung cancer (NSCLC). This real-world study explored treatment patterns and time to receive EGFRm test results in patients with advanced EGFRm NSCLC.

METHODS

A cross-sectional medical chart review was completed May-August 2020 in Australia, Canada, Germany, Italy, South Korea, Taiwan, UK, and USA. Eligible patients had advanced NSCLC and a positive EGFRm test result January-December 2017. Data were abstracted from NSCLC diagnosis to end of follow-up (31 March 2020) or patient's death whichever occurred earlier. The index date was the date of EGFRm confirmation.

RESULTS

223 physicians provided data for 1,793 patients. Patients' mean age was 64.7 years, 54 % were male, 30.7 % had no history of smoking. Overall, 78 % of EGFRm test results were received ≤ 2 weeks after request (range of median 7-14 days across countries). Median time from advanced NSCLC diagnosis to EGFRm test result was 18 days (median range 10-22 days across countries). Over a third (37 %) of patients received a systemic treatment prior to EGFRm result; chemotherapy (25 %) and EGFR-TKI (15 %) were most commonly prescribed; post-EGFR test-result was EGFR-TKI (68 %); 80 % of patients initiated EGFR-TKI at any time point post-NSCLC diagnosis. Of those receiving a first-line EGFR-TKI post-EGFRm testing, 84 % received a TKI alone, 12 % in combination with chemotherapy, and 3 % with other treatments. Median time from first-line EGFR-TKI initiation post-EGFRm testing to first subsequent treatment was 19.8 months.

CONCLUSION

Over one-fifth of patients wait >14 days for their EGFRm test results, affecting their likelihood of receiving first-line EGFR-TKI with 20 % of patients never receiving EGFR TKI treatment. There was significant inter-country variability in the proportion of patients receiving EGFR TKIs. Our study highlights the need to improve EGFRm testing turnaround times and treatment initiation across countries.

Для цитирования: Subramanian Janakiraman, Leighl Natasha B, Choi Yoon-La, Chou Teh-Ying, Gregg Jeffrey, Hui Rina, Marchetti Antonio, Silvey Mark, Makin Rebecca, Gillespie-Akar Liane, Taylor Aliki, Kahangire Doreen A, Bailey Tom, Chau Maiyan, Navani Neal. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.. Lung cancer (Amsterdam, Netherlands). 2022. DOI: 10.1016/j.lungcan.2022.11.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.